Enokizumab
| Enokizumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Enokizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It specifically targets the interleukin-6 (IL-6) pathway, which plays a crucial role in the inflammatory response associated with various autoimmune conditions.
Mechanism of Action[edit]
Enokizumab functions by binding to the IL-6 receptor, thereby inhibiting the interaction of IL-6 with its receptor. This blockade prevents the downstream signaling that leads to inflammation and tissue damage. IL-6 is a cytokine involved in the immune response, and its dysregulation is implicated in diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease.
Clinical Applications[edit]
Enokizumab is primarily used in the management of chronic inflammatory conditions. Its efficacy has been demonstrated in clinical trials for the treatment of:
Pharmacokinetics[edit]
The pharmacokinetic profile of Enokizumab includes its absorption, distribution, metabolism, and excretion. It is typically administered via subcutaneous injection, allowing for direct entry into the bloodstream. The drug has a half-life that supports dosing every two to four weeks, depending on the condition being treated.
Adverse Effects[edit]
Common adverse effects associated with Enokizumab include:
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Elevated liver enzymes
Serious adverse effects may include increased risk of infections due to immunosuppression, and rare cases of gastrointestinal perforation.
Regulatory Status[edit]
Enokizumab has been approved by regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications. Ongoing studies are evaluating its use in other autoimmune conditions.
Research and Development[edit]
Research is ongoing to explore additional therapeutic applications of Enokizumab, including its potential use in oncology and other inflammatory disorders. Studies are also investigating the long-term safety and efficacy of the drug.
Also see[edit]
| Monoclonal antibodies | ||||||||
|---|---|---|---|---|---|---|---|---|
This Monoclonal antibodies related article is a stub.
|
| Hypersensitivity and autoimmune diseases (279.5–6) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
